Will mTOR inhibitors make it as cancer drugs?
- 30 November 2003
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 4 (5), 343-348
- https://doi.org/10.1016/s1535-6108(03)00275-7
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc ExpressionJournal of Biological Chemistry, 2004
- Integration of Growth Factor and Nutrient SignalingMolecular Cell, 2003
- Rheb promotes cell growth as a component of the insulin/TOR signalling networkNature Cell Biology, 2003
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Rheb is an essential regulator of S6K in controlling cell growth in DrosophilaNature Cell Biology, 2003
- Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsOncogene, 2003
- Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cellsOncogene, 2002
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002
- dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1Nature Cell Biology, 2002
- Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in YeastScience, 1991